VNN2

Summary

VNN2 (vanin 2, HGNC:12706) is a protein-coding gene on chromosome 6q23.2, encoding Pantetheine hydrolase VNN2 (O95498). Amidohydrolase that hydrolyzes specifically one of the carboamide linkages in D-pantetheine thus recycling pantothenic acid (vitamin B5) and releasing cysteamine.

This gene product is a member of the Vanin family of proteins that share extensive sequence similarity with each other, and also with biotinidase. The family includes secreted and membrane-associated proteins, a few of which have been reported to participate in hematopoietic cell trafficking. No biotinidase activity has been demonstrated for any of the vanin proteins, however, they possess pantetheinase activity, which may play a role in oxidative-stress response. The encoded protein is a GPI-anchored cell surface molecule that plays a role in transendothelial migration of neutrophils. This gene lies in close proximity to, and in same transcriptional orientation as two other vanin genes on chromosome 6q23-q24. Alternatively spliced transcript variants encoding different isoforms have been described for this gene.

Source: NCBI Gene 8875 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 94 total
• MANE Select transcript: NM_004665

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:12706
Approved symbol	VNN2
Name	vanin 2
Location	6q23.2
Locus type	gene with protein product
Status	Approved
Aliases	FOAP-4, GPI-80
Ensembl gene	ENSG00000112303
Ensembl biotype	protein_coding
OMIM	603571
Entrez	8875

Gene structure

Transcript identifiers

Ensembl transcripts: 16 — 8 nonsense_mediated_decay, 6 protein_coding, 2 protein_coding_CDS_not_defined

ENST00000326499, ENST00000392389, ENST00000418593, ENST00000422400, ENST00000524919, ENST00000525270, ENST00000525289, ENST00000525674, ENST00000526157, ENST00000526192, ENST00000528801, ENST00000530536, ENST00000531279, ENST00000532012, ENST00000532053, ENST00000533835

RefSeq mRNA: 3 — MANE Select: NM_004665 NM_001242350, NM_004665, NM_078488

CCDS: CCDS5161, CCDS5162, CCDS56451

Canonical transcript exons

ENST00000326499 — 7 exons

Exon	Start	End
ENSE00000764068	132752461	132752749
ENSE00003518159	132749695	132749865
ENSE00003561174	132757416	132757546
ENSE00003599181	132743870	132744491
ENSE00003617186	132757671	132757904
ENSE00003628887	132751145	132751518
ENSE00003643444	132755843	132756035

Expression profiles

Bgee: expression breadth ubiquitous, 182 present calls, max score 99.17.

FANTOM5 (CAGE): breadth broad, TPM avg 14.1567 / max 5947.1623, expressed in 364 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
75621	12.9473	256
75623	0.9071	202
75622	0.3022	123

Top tissues by expression

283 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
blood	UBERON:0000178	99.17	gold quality
monocyte	CL:0000576	98.11	gold quality
leukocyte	CL:0000738	98.01	gold quality
mononuclear cell	CL:0000842	97.97	gold quality
granulocyte	CL:0000094	97.46	gold quality
palpebral conjunctiva	UBERON:0001812	96.75	gold quality
periodontal ligament	UBERON:0008266	96.73	gold quality
trabecular bone tissue	UBERON:0002483	94.75	gold quality
right lung	UBERON:0002167	94.00	gold quality
spleen	UBERON:0002106	93.98	gold quality
bone marrow	UBERON:0002371	93.93	gold quality
gall bladder	UBERON:0002110	89.70	gold quality
bone marrow cell	CL:0002092	89.54	gold quality
vermiform appendix	UBERON:0001154	88.40	gold quality
lymph node	UBERON:0000029	87.51	gold quality
upper lobe of left lung	UBERON:0008952	85.36	gold quality
epithelium of nasopharynx	UBERON:0001951	84.82	silver quality
caecum	UBERON:0001153	84.05	gold quality
upper lobe of lung	UBERON:0008948	83.80	gold quality
epithelial cell of pancreas	CL:0000083	82.10	silver quality
nasal cavity epithelium	UBERON:0005384	81.68	silver quality
islet of Langerhans	UBERON:0000006	80.37	gold quality
adrenal tissue	UBERON:0018303	80.02	gold quality
epithelium of bronchus	UBERON:0002031	79.95	gold quality
bronchus	UBERON:0002185	79.24	gold quality
bronchial epithelial cell	CL:0002328	78.68	gold quality
germinal epithelium of ovary	UBERON:0001304	78.43	silver quality
tonsil	UBERON:0002372	77.34	gold quality
lung	UBERON:0002048	77.24	gold quality
omental fat pad	UBERON:0010414	76.77	gold quality

Single-cell (SCXA)

Detected in 4 experiment(s), a significant marker in 3.

Experiment	Marker?	Max mean expression
E-MTAB-9801	yes	4651.47
E-MTAB-9221	yes	20.46
E-ANND-3	yes	7.47
E-HCAD-30	no	49.87

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

23 targeting VNN2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-205-3P	99.92	69.92	3165
HSA-MIR-3671	99.90	73.04	3897
HSA-MIR-944	99.82	70.85	3042
HSA-MIR-2116-3P	99.74	64.32	889
HSA-MIR-298	99.63	67.56	1916
HSA-MIR-129-1-3P	98.86	68.41	779
HSA-MIR-129-2-3P	98.86	68.41	779
HSA-MIR-513B-3P	98.76	68.12	1577
HSA-MIR-3135B	98.61	65.33	1470
HSA-MIR-4662A-5P	98.48	67.18	1007
HSA-MIR-4772-3P	98.04	65.60	1203
HSA-MIR-1322	97.98	68.96	625
HSA-MIR-3157-5P	97.41	67.61	998
HSA-MIR-3663-5P	97.01	64.84	713
HSA-MIR-6886-3P	96.96	66.36	844
HSA-MIR-3184-3P	96.96	66.91	845
HSA-MIR-4750-3P	96.65	64.38	512
HSA-MIR-1291	96.28	65.89	1224
HSA-MIR-6775-3P	95.76	65.91	982
HSA-MIR-3651	95.62	64.67	287
HSA-MIR-4765	93.11	66.17	737

Literature-anchored findings (GeneRIF, showing 11)

• DMSO induces neutrophil differentiation and provides suitable conditions for GPI-80 expression; this culture system is a model for the regulation of GPI-80 expression during myeloid differentiation. (PMID:12749849)
• GPI-80 positive monocytes belong to a monocyte subpopulation that is superior in phagocytosis and reactive oxygen production, but inferior in antigen presentation (PMID:12777063)
• elevated GPI-80 expression is associated with development and progression of thymoma (PMID:12967480)
• some of the GPI-80 on pseudopodia of migrating neutrophils during the late phase was associated with urokinase-type plasminogen activator receptor (uPAR), a regulator of beta2 integrin-dependent adherence and migration (PMID:14748512)
• analysis of structural divergence of GPI-80 in activated human neutrophils (PMID:17543284)
• GPI-80 defines a subpopulation of human fetal liver hematopoietic stem/progenitor cells (HSPCs) with self-renewal ability. (PMID:25465114)
• the GPI-80 CV in the CD16(hi) population was correlated inversely with the proliferative ability of T cells and the GPI-80 MFI of the CD33(hi) population was correlated with reactive oxygen species production. These results led us to propose that the pattern of GPI-80 expression in these populations is a simple and useful marker for unusual differentiation, which is related to MDSC functions. (PMID:27569996)
• Low VNN2 expression is associated with invasion of osteosarcoma. (PMID:30066949)
• the expression of GPI-80 on myeloid cells, a useful index for the heterogeneity of Myeloid-derived suppressor cells, serves as a potential prognostic biomarker for Metastatic Renal Cell Carcinoma. (PMID:31776298)
• The hematopoietic stem cell marker VNN2 is associated with chemoresistance in pediatric B-cell precursor ALL. (PMID:32853382)
• GPI-80 Augments NF-kappaB Activation in Tumor Cells. (PMID:34769456)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
drosophila_melanogaster	Btnd	FBGN0029848
drosophila_melanogaster	vanin-like	FBGN0040069
drosophila_melanogaster	CG32750	FBGN0052750
drosophila_melanogaster	CG32751	FBGN0052751

Paralogs (2): VNN1 (ENSG00000112299), BTD (ENSG00000169814)

Protein

Protein identifiers

Pantetheine hydrolase VNN2 — O95498 (reviewed: O95498)

Alternative names: Glycosylphosphatidyl inositol-anchored protein GPI-80, Protein FOAP-4, Vascular non-inflammatory molecule 2

All UniProt accessions (10): B4DQB2, E9PK31, E9PL76, E9PLK5, E9PQ75, E9PRD9, O95498, J3KQ55, J3KQQ7, J3QT03

UniProt curated annotations — full annotation on UniProt →

Function. Amidohydrolase that hydrolyzes specifically one of the carboamide linkages in D-pantetheine thus recycling pantothenic acid (vitamin B5) and releasing cysteamine. Involved in the thymus homing of bone marrow cells. May regulate beta-2 integrin-mediated cell adhesion, migration and motility of neutrophil.

Subcellular location. Cell membrane.

Tissue specificity. Widely expressed with higher expression in spleen and blood.

Miscellaneous. May be produced at very low levels due to a premature stop codon in the mRNA, leading to nonsense-mediated mRNA decay. May be produced at very low levels due to a premature stop codon in the mRNA, leading to nonsense-mediated mRNA decay. May be produced at very low levels due to a premature stop codon in the mRNA, leading to nonsense-mediated mRNA decay.

Similarity. Belongs to the carbon-nitrogen hydrolase superfamily. BTD/VNN family.

Isoforms (6)

UniProt ID	Names	Canonical?
O95498-1	1	yes
O95498-2	2, GPI-80 variant protein 3
O95498-3	3, GPI-80 variant protein 2
O95498-4	4, GPI-80 variant protein 1
O95498-5	5, GPI-80 variant protein 4
O95498-6	6

RefSeq proteins (3): NP_001229279, NP_004656, NP_511043 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR003010	C-N_Hydrolase	Domain
IPR012101	Biotinidase-like_euk	Family
IPR036526	C-N_Hydrolase_sf	Homologous_superfamily
IPR040154	Biotinidase/VNN	Family
IPR043957	Vanin_C	Domain

Pfam: PF00795, PF19018

Enzyme classification (BRENDA):

• EC 3.5.1.92 — pantetheine hydrolase (BRENDA: 6 organisms, 31 substrates, 43 inhibitors, 6 Km, 0 kcat entries)

Substrate kinetics (BRENDA)

4 substrates with measured Km, best-characterized 4. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
PANTOTHENATE-7-AMIDO-4-METHYLCOUMARIN	13–28	2
(R)-PANTETHEINE	0.02	1
PANTETHEINE	5	1
S-CYSTEAMINE-3-PYRUVATE	—	1

Catalyzed reactions (Rhea), 1 shown:

• (R)-pantetheine + H2O = cysteamine + (R)-pantothenate (RHEA:13445)

UniProt features (29 total): splice variant 8, glycosylation site 6, sequence variant 6, active site 3, signal peptide 1, chain 1, propeptide 1, sequence conflict 1, domain 1, lipid moiety-binding region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O95498-F1	92.06	0.83

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (3): 80 (proton acceptor); 179 (proton donor); 211 (nucleophile)

Post-translational modifications (1): 493

Glycosylation sites (6): 347, 357, 411, 468, 39, 273

Function

Pathways and Gene Ontology

Reactome pathways

2 pathways

ID	Pathway
R-HSA-163125	Post-translational modification: synthesis of GPI-anchored proteins
R-HSA-199220	Vitamin B5 (pantothenate) metabolism

MSigDB gene sets: 168 (showing top): GSE45365_NK_CELL_VS_CD8A_DC_MCMV_INFECTION_UP, DAVIES_MULTIPLE_MYELOMA_VS_MGUS_DN, GOBP_MONOCARBOXYLIC_ACID_METABOLIC_PROCESS, HUTTMANN_B_CLL_POOR_SURVIVAL_DN, RHEIN_ALL_GLUCOCORTICOID_THERAPY_UP, GOBP_AMIDE_METABOLIC_PROCESS, MODULE_99, SCHLOSSER_SERUM_RESPONSE_DN, GOBP_ORGANIC_ACID_METABOLIC_PROCESS, AACTTT_UNKNOWN, GOBP_MODIFIED_AMINO_ACID_METABOLIC_PROCESS, GOCC_SIDE_OF_MEMBRANE, SMID_BREAST_CANCER_LUMINAL_B_DN, REACTOME_METABOLISM_OF_VITAMINS_AND_COFACTORS, chr6q23

GO Biological Process (1): pantothenate metabolic process (GO:0015939)

GO Molecular Function (4): pantetheine hydrolase activity (GO:0017159), protein binding (GO:0005515), hydrolase activity (GO:0016787), hydrolase activity, acting on carbon-nitrogen (but not peptide) bonds, in linear amides (GO:0016811)

GO Cellular Component (4): extracellular region (GO:0005576), plasma membrane (GO:0005886), side of membrane (GO:0098552), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
Post-translational protein modification	1
Metabolism of water-soluble vitamins and cofactors	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
membrane	2
modified amino acid metabolic process	1
monocarboxylic acid metabolic process	1
hydrolase activity, acting on carbon-nitrogen (but not peptide) bonds, in linear amides	1
binding	1
catalytic activity	1
hydrolase activity, acting on carbon-nitrogen (but not peptide) bonds	1
cell periphery	1
leaflet of membrane bilayer	1

Protein interactions and networks

STRING

1750 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
VNN2	SERPINE2	P07093	619
VNN2	AHSA1	O95433	492
VNN2	SMG5	Q9UPR3	479
VNN2	SRY	Q05066	435
VNN2	SULT1C2	O00338	398
VNN2	RGS2	P41220	390
VNN2	GLRX	P35754	381
VNN2	CYP4B1	P13584	380
VNN2	SRXN1	Q9BYN0	375
VNN2	CHRNA4	P43681	371
VNN2	RECQL4	O94761	366
VNN2	RETN	Q9HD89	360
VNN2	ENO1	P06733	353
VNN2	H2AX	P16104	353
VNN2	MMP12	P39900	353
VNN2	MCL1	Q07820	353
VNN2	CAPN10	Q9HC96	353

IntAct

18 interactions, top by confidence:

A	B	Type	Score
PRKCA	VNN2	psi-mi:“MI:0915”(physical association)	0.560
VNN2	YWHAG	psi-mi:“MI:0915”(physical association)	0.560
VNN2	SETDB1	psi-mi:“MI:0915”(physical association)	0.560
KAT5	VNN2	psi-mi:“MI:0915”(physical association)	0.560
LMO3	VNN2	psi-mi:“MI:0915”(physical association)	0.560
VNN2	ATP2A1	psi-mi:“MI:0914”(association)	0.350

BioGRID (79): ACADVL (Affinity Capture-MS), FKBP14 (Affinity Capture-MS), COX18 (Affinity Capture-MS), FZD3 (Affinity Capture-MS), S1PR5 (Affinity Capture-MS), CLDND1 (Affinity Capture-MS), KLK7 (Affinity Capture-MS), ATP2A1 (Affinity Capture-MS), FZD6 (Affinity Capture-MS), FZD7 (Affinity Capture-MS), CTSV (Affinity Capture-MS), PIGU (Affinity Capture-MS), DPY19L4 (Affinity Capture-MS), ECEL1 (Affinity Capture-MS), SLC30A9 (Affinity Capture-MS)

ESM2 similar proteins: A5PJN5, A6QQ07, B2RXS4, O08590, O15031, O35632, O95497, O95498, P09172, P14616, P15101, P19801, P26011, P36633, P43251, P83548, Q3SZL5, Q3V5L5, Q4R7M2, Q58CQ9, Q5FVF9, Q5R8R3, Q5XI31, Q64237, Q64716, Q6PD26, Q765H6, Q76HN1, Q8AV84, Q8BG22, Q8CIF4, Q8IRR1, Q8JZQ5, Q8NFI3, Q8SQG7, Q91ZJ9, Q9BDJ5, Q9DA79, Q9DBX3, Q9H3S1

Diamond homologs: A6QQ07, C6KYS2, O95497, O95498, P43251, Q58CQ9, Q5FVF9, Q8AV84, Q8CIF4, Q9BDJ5, Q9QZ25, Q9TSX8, Q9Z0K8, P83548, Q8IRR1, Q9NFP1, Q9UYV8, P49954

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

94 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	74
Likely benign	5
Benign	3

Top pathogenic / likely-pathogenic (0)

SpliceAI

882 predictions. Top by Δscore:

Variant	Effect	Δscore
6:132749689:TCTTA:T	donor_loss	1.0000
6:132749690:CTTA:C	donor_loss	1.0000
6:132749691:TTA:T	donor_loss	1.0000
6:132749692:TA:T	donor_loss	1.0000
6:132749693:A:AC	donor_gain	1.0000
6:132749694:C:CA	donor_loss	1.0000
6:132749694:C:CC	donor_gain	1.0000
6:132749694:CCT:C	donor_gain	1.0000
6:132749861:CAGAC:C	acceptor_gain	1.0000
6:132749863:GACC:G	acceptor_loss	1.0000
6:132749864:ACCT:A	acceptor_loss	1.0000
6:132749865:CCTA:C	acceptor_gain	1.0000
6:132749866:C:CC	acceptor_gain	1.0000
6:132749867:T:G	acceptor_loss	1.0000
6:132749868:A:AC	acceptor_gain	1.0000
6:132749868:A:C	acceptor_gain	1.0000
6:132755839:TTACC:T	donor_loss	1.0000
6:132755840:TACC:T	donor_loss	1.0000
6:132755841:A:T	donor_loss	1.0000
6:132756036:C:CC	acceptor_gain	1.0000
6:132756042:CAAAT:C	acceptor_gain	1.0000
6:132757414:ACCTG:A	donor_loss	1.0000
6:132757542:GCACC:G	acceptor_gain	1.0000
6:132757543:CACC:C	acceptor_gain	1.0000
6:132757543:CACCC:C	acceptor_gain	1.0000
6:132757544:ACC:A	acceptor_gain	1.0000
6:132757545:CC:C	acceptor_gain	1.0000
6:132757545:CCC:C	acceptor_gain	1.0000
6:132757545:CCCTG:C	acceptor_loss	1.0000
6:132757546:CCTG:C	acceptor_gain	1.0000

AlphaMissense

3407 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
6:132751514:A:C	S277R	0.991
6:132751514:A:T	S277R	0.991
6:132751516:T:G	S277R	0.991
6:132756002:G:C	S126R	0.989
6:132756002:G:T	S126R	0.989
6:132756004:T:G	S126R	0.989
6:132752527:A:G	W254R	0.985
6:132752527:A:T	W254R	0.985
6:132755853:C:G	R176P	0.983
6:132755857:C:G	A175P	0.983
6:132757799:C:G	A29P	0.983
6:132755994:G:T	A129D	0.982
6:132755843:C:A	K179N	0.978
6:132755843:C:G	K179N	0.978
6:132755868:C:A	G171V	0.978
6:132752649:T:A	D213V	0.976
6:132749862:A:G	C402R	0.975
6:132752649:T:G	D213A	0.975
6:132752650:C:G	D213H	0.975
6:132752654:G:C	C211W	0.975
6:132752723:A:C	F188L	0.974
6:132752723:A:T	F188L	0.974
6:132752725:A:G	F188L	0.974
6:132755881:A:C	Y167D	0.974
6:132751246:A:G	C367R	0.970
6:132744417:C:A	R482S	0.969
6:132744417:C:G	R482S	0.969
6:132755869:C:G	G171R	0.969
6:132755869:C:T	G171R	0.969
6:132755883:A:T	V166E	0.969

dbSNP variants (sampled 300 via entrez): RS1000216262 (6:132749459 A>C), RS1000281253 (6:132764998 T>C,G), RS1000447346 (6:132765252 C>G), RS1000667971 (6:132748588 A>C), RS1000929920 (6:132755384 T>C), RS1001164080 (6:132750186 G>A), RS1001316652 (6:132748401 A>C), RS1001427200 (6:132750603 G>A), RS1001498438 (6:132753628 T>A,C), RS1001665973 (6:132749586 G>A), RS1001845842 (6:132753325 C>T), RS1001871909 (6:132757668 T>A), RS1002151096 (6:132762342 G>T), RS1002221195 (6:132747099 T>C), RS1002226289 (6:132760240 T>A,G)

Disease associations

OMIM: gene MIM:603571 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): prostate cancer (MONDO:0008315)

Orphanet (1): Familial prostate cancer (Orphanet:1331)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

25 total (human), top 25 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Acetaminophen	decreases expression	2
Tobacco Smoke Pollution	decreases expression, affects expression	2
Antirheumatic Agents	decreases expression	2
triphenyl phosphate	affects expression	1
bisphenol A	increases methylation	1
epigallocatechin gallate	decreases expression	1
di-n-butylphosphoric acid	affects expression	1
CGP 52608	affects binding, increases reaction	1
abrine	decreases expression	1
gardiquimod	increases expression, decreases reaction	1
Zoledronic Acid	increases expression	1
Air Pollutants	increases abundance, affects expression	1
Air Pollutants, Occupational	decreases expression	1
Arsenic	affects methylation	1
Benzo(a)pyrene	increases methylation	1
Hydrogen Peroxide	affects expression	1
Nickel	decreases expression	1
Ozone	affects expression, increases abundance	1
Silicon Dioxide	increases expression	1
Tetrachlorodibenzodioxin	decreases expression	1
Tretinoin	increases expression	1
Cyclosporine	decreases expression	1
Aflatoxin B1	increases methylation	1
Palmitic Acid	decreases expression	1
Protein Kinase Inhibitors	decreases reaction, increases expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer